Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 4

​Tsinghua University holds Tsinghua AI Agent Hospital Inauguration and 2025 Tsinghua Medicine Townhall Meeting-Tsinghua University

On the morning of April 26, Tsinghua University held an inauguration ceremony for Tsinghua AI Agent Hospital and the 2025 Tsinghua Medicine Townhall Meeting at the Main Building Reception Hall. Tsinghua President Li Luming and Vice President Wang Hongwei attended the event.

President Li Luming reviewed the progress of Tsinghua University’s medical programs over the past year, emphasizing the University’s strong commitment to the development of medical disciplines. He highlighted Tsinghua’s strength in fundamental research in Artificial intelligence, which has already led to a series of high-level innovations at the intersection of AI and medicine. The establishment of the Tsinghua AI Agent Hospital represents a new initiative by Tsinghua to leverage its strengths in science and engineering to empower the advancement of medicine.

President Li encouraged Tsinghua Medicine to remain committed to fostering virtue and talent, cultivating a new generation of medical innovators with both a strong medical foundation and AI literacy. He also called for deeper integration across disciplines, particularly between engineering and medicine, as well as closer ties between clinical practice and technology. Finally, he urged Tsinghua Medicine to align its work with cutting-edge global trends and national strategic needs, driving medical advancement and contributing to the protection of public health.

CRISPR uncovers gene that supercharges vitamin D—and stops tumors in their tracks

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their survival but also disrupted thousands of other genes tied to cancer and metabolism. This opens the door to highly targeted cancer therapies—by either cutting off vitamin D supply to tumors or enhancing the gene’s activity to boost health. The findings hint at vast possibilities in treating diseases influenced by vitamin D, though long-term impacts remain uncertain.

Guselkumab demonstrates superior efficacy in clinical trials, offering new hope to Crohn’s disease patients

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief.

These findings from two pivotal Phase III known as GALAXI 2 and 3, published in The Lancet, provided the basis for the recent Food and Drug Administration approval of guselkumab (brand name Tremfya) for the treatment of moderately to severely active Crohn’s disease.

Crohn’s disease affects roughly 780,000 people in the United States and often requires a lifetime of management. Despite numerous available biologic medications, many patients fail to achieve sustained remission. Guselkumab blocks the interleukin-23 (IL-23) pathway, a key driver of chronic intestinal inflammation.

Gene essential for vitamin D absorption could help unlock treatments for cancer and autoimmune diseases

Vitamin D is not only an essential nutrient, but also the precursor of the hormone calcitriol, indispensable for health. It regulates the uptake of phosphate and calcium necessary for bones by the intestines, as well as cell growth and the proper function of muscles, nerve cells, and the immune system.

Now, researchers have shown for the first time in Frontiers in Endocrinology that a particular gene called SDR42E1 is crucial for taking up vitamin D from the gut and further metabolizing it—a discovery with many possible applications in precision medicine, including .

“Here we show that blocking or inhibiting SDR42E1 may selectively stop the growth of cancer cells,” said Dr. Georges Nemer, a professor and associate dean for research at the University College of Health and Life Sciences at Hamad Bin Khalifa University in Qatar, and the study’s corresponding author.

Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia

LONDON, Ont. – Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol — a cough medicine used safely for decades in Europe — can slow dementia in people with Parkinson’s disease.

Published today in the prestigious JAMA Neurology, this 12-month clinical trial involving 55 participants with Parkinson’s disease dementia (PDD) monitored memory, psychiatric symptoms and GFAP, a blood marker linked to brain damage.

Parkinson’s disease dementia causes memory loss, confusion, hallucinations and mood changes. About half of those diagnosed with Parkinson’s develop dementia within 10 years, profoundly affecting patients, families and the health care system.

MRI study reveals structural brain changes in children with restrictive eating disorders

In the last decade, the incidence of restrictive eating disorders in children, like anorexia-nervosa and avoidant/restrictive food intake disorders (ARFID), has doubled. These disorders have severe consequences for growing children, resulting in nutritional deficiencies and problems with bone development, statural growth and puberty. Most studies have focused on the effects of these disorders in older individuals, and little is currently known about how restrictive eating disorders affect the brain in children or what mechanisms in the brain might be responsible for this restrictive eating behavior.

To get a better understanding of how these early-onset eating disorders work in the brain, researcher Clara Moreau and her team conducted MRI brain scans on 290 , of which 124 had been hospitalized for early-onset anorexia-nervosa (EO-AN), 50 had been hospitalized for ARFID, and 116 were children with no eating disorders. All participants were under 13 years old, and those who were hospitalized had very low body mass index (BMI) due to restrictive eating. The results were published in Nature Mental Health.

Although EO-AN and AFRID both result in low BMI and malnutrition due to restrictive eating, they are distinct disorders. EO-AN—as well as later onset anorexia-nervosa—is characterized by restrictive eating arising from a distorted body image, while restrictive eating in AFRID arises from sensory issues, such as a dislike of certain food textures, a lack of interest in food or fear of negative health consequences from food. These differences indicate that the disorders probably arise from different mechanisms in the brain.

How the Brain Increases Blood Flow on Demand

All day long, our brains carry out complicated and energy-intensive tasks such as remembering, solving problems, and making decisions.

To supply the energy these tasks require while conserving this precious fuel, the brain has evolved a system that allows it to quickly and efficiently send blood only to the areas that need it most in any given moment. This system is essential to brain function and overall health, yet how it works has remained somewhat of a mystery.

Now, a team led by researchers at Harvard Medical School has uncovered new details of how the brain moves blood to active areas in real time. Their findings are published July 16 in Cell.

In experiments in mice, the team discovered that the brain uses specialized channels in the lining of its blood vessels to communicate where blood is needed.

“This work helps us understand how you can get that super-important blood supply to the correct areas of the brain on a time scale that is useful,” said co-lead author Luke Kaplan, a research fellow in neurobiology in the Blavatnik Institute at HMS.

If confirmed in additional studies in animals and humans, the findings could be used to better understand findings on brain imaging tests such as functional MRI (fMRI). The insights may also advance understanding of neurodegenerative diseases, in which this communication system often breaks down, leading to cognitive problems.

Continue reading “How the Brain Increases Blood Flow on Demand” | >

Krembil Brain Institute researchers identify new model of Alzheimer’s as an autoimmune disease

(Toronto, Sept. 27, 2022) – Scientists at the Krembil Brain Institute, part of the University Health Network, have proposed a new mechanistic model (AD2) for Alzheimer’s, looking at it not as a brain disease, but as a chronic autoimmune condition that attacks the brain.

This novel research is published today, in Alzheimer’s & Dementia.

“We don’t think of Alzheimer’s as fundamentally a disease of the brain. We think of it as a disease of the immune system within the brain,” says Dr. Donald Weaver, co-Director of the Krembil Brain Institute and author of the paper.

Alzheimer’s disease, the most common form of dementia, impacts more than 50 million people around the world, with a new person being diagnosed every three seconds. Yet, despite more than 200 clinical trials in the past 30 years, there are no disease modifying therapeutics to prevent, halt or treat Alzheimer’s.

(Circa 2022 the immune function and immune molecules have been focused on recently making immunotherapy targets interesting consdering they can help remove plaques)

Circadian disruption by night light linked to multiple cardiovascular outcomes

Flinders Health and Medical Research Institute researchers, along with colleagues in the UK and U.S., have linked brighter night-time light exposure to elevated risks of five major cardiovascular diseases.

Circadian rhythms govern fluctuations in blood pressure, heart rate, platelet activation, hormone secretion, and glucose metabolism. Long-term disruption of those rhythms in animal and human studies have produced myocardial fibrosis, hypertension, inflammation, and impaired autonomic balance. Previous research efforts relied largely on satellite-derived estimates or small cohorts using bedroom or wrist light sensors, leaving personal exposure patterns uncharted at population scale.

In the study, “Personal night light exposure predicts incidence of cardiovascular diseases in 88,000 individuals,” posted on medRxiv, researchers conducted a prospective cohort analysis to assess whether day and night light exposure predicts incidence of cardiovascular diseases and whether relationships vary with genetic susceptibility, sex, and age.

Antibody sIgM emerges as a key guardian of gut health and metabolism

A pioneering new study published in Nature Microbiology, led by J. Oriol Sunyer, professor of immunology and pathobiology at the School of Veterinary Medicine, and a team of researchers at Penn Vet and the University of New Mexico, has uncovered a surprising new player in gut health: an antibody called secretory immunoglobulin M (sIgM).

While another antibody, secretory immunoglobulin A (sIgA), has long been known for helping balance the bacteria in our intestines, this new research shows that sIgM may be just as vital—if not more so—in protecting gut health and maintaining overall well-being.

Secretory immunoglobulins—immunoglobulins found in the mucosal surfaces or linings of various organs and tracts of vertebrates—modulate the colonization, composition, and metabolism of the gut microbiome. While sIgA and secretory immunoglobulin T (sIgT) are considered the key immunoglobulins involved in the maintenance of microbiome homeostasis in the gut of mammals and fish, respectively, Sunyer and his colleagues challenged this paradigm by demonstrating that sIgM plays a crucial and non-redundant role in the regulation of gut microbiota and metabolism.